Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0620720230290010050
Natural Product Sciences
2023 Volume.29 No. 1 p.50 ~ p.58
Secondary Metabolites from Anthonotha cladantha (Harms) J.Leonard
Laurent Voufack Lefack Bongmo

Achille Nouga Bissoue
Samuel Magloire Bissim
Georges Bellier Tabekoueng
Willifred Dongmo Tekapi Tsopgni
Mehreen Lateef
Felicien Mushagalusa Kasali
Muhammad Shaiq Ali
Alain Francois Kamdem Waffo
Jean Duplex Wansi
Abstract
The phytochemical investigation of the crude methanolic extracts roots and stem bark of Anthonotha cladantha (Harms) J.Leonard led to the isolation and identification of twelve secondary metabolites: 2,3-dihydroxypropyl hexacosanoate (1), hederagenine (2), cycloeucalenol (3), 2¥á-hydroxylupeol (4), betulinic acid (5), lupeol (6), heptacosan-2-one (7), triacontanoic acid (8), stigmast-4-en-3-one (9), ¥â-sitosterol (10), stigmasterol (11), and stigmasterol-3-O-¥â-D-glucopyranoside (12). Their structures were elucidated with the help of their spectroscopic and physical data and by comparison with those reported in the literature. To the best of our knowledge, from all those compounds, 2,3-dihydroxypropyl hexacosanoate (1), hederagenine (2), cycloeucalenol (3), 2¥á-hydroxylupeol (4), and betulinic acid (5) are being reported for the first time from this genus. In addition, the acetylation of compound 1 afforded a new derivative 3-(hexacosanoyloxy)propane-1,2-diyl diacetate (1a). Compound 1 possessed a moderate ¥á-glucosidase inhibitory activity with an IC50 value of 39.2 ¡¾ 0.22 ¥ìM; it neither showed antioxidant activity nor inhibition against the enzyme urease. Compound 1a exhibited weak antioxidant activity in the DPPH assay with an IC50 value of 80.3 ¡¾ 0.83 ¥ìM but was inactive against ¥á-glucosidase and urease. Furthermore, both compounds 1 and 1a were inactive against seven pathogenic bacterial strains.
KEYWORD
3-(hexacosanoyloxy)propane-1, 2-diyl diacetate, Anthonotha cladantha, Biological screening, Fabaceae, Secondary metabolites
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed